Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure
Christopher M. O’Connor(Inova Health System), for the HF-ACTION Investigators(Unknown), William E. Kraus(Duke Medical Center), David J. Whellan(Thomas Jefferson University), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Ileana L. Piña(American Heart Association), Dalane W. Kitzman(Wake Forest University), Robert S. McKelvie(McMaster University Medical Centre), Steven J. Keteyian(Henry Ford Health System), Lawton S. Cooper(Atrium Health Wake Forest Baptist), David S. Rendall(Duke University), Eric Leifer(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Kevin A. Schulman(Stanford University), Stephen J. Ellis(Duke University), Nancy Houston Miller(Palo Alto University), Kerry L. Lee(Clinical Research Institute), James A. Blumenthal(Duke Medical Center), Jerome L. Fleg(National Heart Lung and Blood Institute)
Cited by 2,164
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|Survey of Anesthesiology|2000|2.9k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k